Anatomy hub
Spine: Options and What the Evidence Actually Shows
Low back pain and degenerative disc disease drive enormous search volume. Care is usually multimodal — and regenerative options belong in a careful clinical conversation.
Anatomy and clinical context
The lumbar spine bears load through discs, facet joints, ligaments, and musculature. Disc degeneration and facet arthropathy are common imaging findings that do not always match pain severity.
Most guidelines emphasize education, activity, physical therapy, and judicious medications before interventional procedures. Regenerative injectates are sometimes offered for discogenic or facet-mediated pain in specialized practices — evidence remains evolving and heterogeneous.
Illustration of the lumbar spine
The standard-of-care ladder
Conservative care first, then injections, then surgery when indicated. Cell therapy belongs in that conversation — not above it.
- Step 1
Conservative care
Education, graded activity, physical therapy, cognitive approaches to chronic pain, and short-course medications when appropriate.
- Step 2
Injections
Epidural steroids, facet injections, radiofrequency ablation, and in selected practices orthobiologic or cell-based injectates under imaging guidance.
- Step 3
Surgery
Decompression, fusion, or disc arthroplasty for clear structural indications after failure of nonoperative care.
Where cell therapy fits
Spine regenerative literature is thinner and more heterogeneous than knee OA. Patients deserve clear framing: same-day products are not proven disease-modifiers for disc degeneration at scale, and surgical candidacy is a physician decision.
- Low back pain is multifactorial — imaging alone rarely dictates the regenerative story.
- Same-day unexpanded products face the same dose and potency limits discussed across orthopedics.
- Banking younger MSCs preserves optionality if future protocols require therapeutic cell numbers your physician cannot harvest same-day.
Selected citations
MILES
Mautner et al. · Nature Medicine (2023)
n=440 knee OA trial: BMAC, umbilical tissue, and SVF vs corticosteroid — none beat steroid at one year; none moved MRI scores.
Shapiro 2017
Shapiro et al. · AJSM (2017)
BMAC vs saline in the same patient's other knee — no difference on primary outcomes.
Why dose and donor age change the picture
The trials that disappoint used unexpanded cells from older donors.
The ones that work used expanded cells at therapeutic dose. Dose is the variable — and dose is what expansion buys you. Potency is what your age buys you.
- 1
Cells work at dose.
A same-day draw yields a small, uncounted, unexpanded fraction. Expansion turns one draw into many doses.
- 2
Potency is age-dependent, and it is a one-way door.
Your MSCs at 35 are not your MSCs at 55. Banking is the only mechanism that makes 35-year-old cells available to a 55-year-old.
- 3
Expansion is what makes the bank a supply, not a souvenir.
Bank once, expand repeatedly, across a treatment course rather than a single shot. Culture expansion for Forever Labs members is rolling out — starting with selected states as our Florida cGMP lab comes online.
- 4
The provider decides what happens next.
We supply cells; they practice medicine. Forever Labs does not treat conditions — your physician owns the clinical relationship.
Two next steps — equal weight
Forever Labs does not treat conditions. Your physician owns the clinical relationship. We bank cells and, as expansion rolls out, help make dose possible.